| 135 | 2025-10-12 | IBIO | 65 | Strategic Shift Poised To Propel IBio's Clinical And Market Prospects | 0.7913 | 1.50 | 90% | 2025-11-01 | 2026-05-01 | 181 | 12 |
| 134 | 2025-10-12 | AEMD | 65 | Aethlon Medical Poised For Breakthrough With Hemopurifier Trials | 0.6932 | 3.00 | 333% | 2025-11-01 | 2026-06-30 | 241 | 5 |
| 133 | 2025-09-19 | VRCA | 70 | Verrica Set For Surge As Phase 3 Trials Commence | 4.04 | 6.50 | 61% | 2025-10-25 | 2026-01-10 | 77 | 49 |
| 132 | 2025-09-14 | ATNM | 70 | Actinium Poised For Growth With Upcoming AML Trial Results | 1.63 | 2.50 | 53% | 2025-10-01 | 2025-12-31 | 91 | 51 |
| 131 | 2025-09-14 | PMVP | 65 | PMV Pharma Set To Transform Ovarian Cancer Treatment | 1.23 | 9.25 | 652% | 2026-12-25 | 2027-04-05 | 101 | 55 |
| 130 | 2025-09-10 | CLRB | 70 | Cellectar Set For Regulatory Breakthrough With EMA Decision | 5.00 | 12.50 | 150% | 2025-09-25 | 2025-10-10 | 15 | 14 |
| 129 | 2025-09-10 | MGNX | 65 | MacroGenics Set For Potential Upswing Amid Clinical Advances | 1.72 | 4.00 | 133% | 2025-09-20 | 2025-11-30 | 71 | 80 |
| 128 | 2025-09-10 | DMAC | 65 | DiaMedica Poised For Breakthrough With Upcoming ReMEDy2 Trial Results | 7.21 | 12.33 | 71% | 2026-02-01 | 2026-06-30 | 149 | 163 |
| 127 | 2025-09-10 | LXRX | 60 | Lexicon Poised For Growth With Promising Neuropathic And Diabetes Treatments | 1.13 | 2.50 | 121% | 2025-09-15 | 2026-01-15 | 122 | 338 |
| 126 | 2025-09-10 | CDXS | 75 | Codexis Gears Up For Major Breakthrough With ECO Synthesis Platform | 2.45 | 8.00 | 227% | 2025-10-25 | 2025-11-15 | 21 | 209 |
| 125 | 2025-07-29 | IMDX | 80 | IMDX Set For Surge As FDA Decision Nears On GraftAssureDx | 2.79 | 6.50 | 133% | 2025-11-01 | 2025-12-31 | 60 | 86 |
| 124 | 2025-07-28 | ADAP | 70 | Adaptimmune Set For Breakout With Pending FDA Approval UPDATE | 0.1000 | 1.50 | 1400% | 2025-07-31 | 2025-08-05 | 5 | 64 |
| 123 | 2025-07-08 | ARTL | 65 | Artelo Poised For Breakout With Upcoming Clinical Trials | 14.32 | 25.00 | 75% | 2025-08-01 | 2025-12-31 | 152 | 7 |
| 122 | 2025-07-08 | BFRI | 70 | Biofrontera Set For Breakout Amid Promising Clinical Trials | 0.6949 | 1.20 | 73% | 2025-07-28 | 2025-12-31 | 156 | 7 |
| 121 | 2025-07-08 | DRMA | 65 | Dermata Set For Breakout On Imminent FDA Approval And Strategic Partnerships | 6.95 | 30.00 | 332% | 2025-07-15 | 2025-08-30 | 46 | 4 |
| 120 | 2025-07-08 | LPTX | 65 | Leap Therapeutics Poised For Breakout With Strategic Review And Sirexatamab Trials | 0.2838 | 5.50 | 1838% | 2025-09-01 | 2025-12-31 | 121 | 12 |
| 119 | 2025-07-08 | EQ | 65 | Equillium Set For Significant Upswing Amid Itolizumab Trial Results | 0.3190 | 1.25 | 292% | 2025-07-15 | 2025-08-30 | 46 | 12 |
| 118 | 2025-07-08 | ENFY | 65 | Enlightify Set To Transform With Blockchain Integration And Strong Agricultural Roots | 1.10 | 1.65 | 50% | 2025-08-01 | 2025-08-31 | 30 | 18 |
| 117 | 2025-07-08 | TLPH | 65 | Talphera Nears Potential Breakthrough With Niyad Clinical Advancements | 0.4630 | 1.20 | 159% | 2025-09-25 | 2025-12-31 | 97 | 9 |
| 116 | 2025-07-07 | BTAI | 70 | Anticipating Breakout: BioXcel's SERENITY Trial Could Revolutionize Treatment | 1.90 | 4.50 | 137% | 2025-07-15 | 2025-09-30 | 77 | 12 |
| 115 | 2025-07-07 | IRD | 65 | Opus Genetics Set For Breakthrough With Upcoming Clinical Results | 0.9921 | 3.50 | 253% | 2025-10-01 | 2025-12-31 | 91 | 56 |
| 114 | 2025-07-07 | TTNP | 60 | Titan Pharma Poised For Breakout On Clinical Success | 4.45 | 7.50 | 69% | 2025-09-05 | 2025-12-25 | 111 | 6 |
| 113 | 2025-07-07 | ATNF | 65 | 180 Life Sciences Poised For Strategic Shift And Potential Revenue Boost | 0.7997 | 1.50 | 88% | 2025-07-15 | 2025-08-30 | 46 | 5 |
| 112 | 2025-07-07 | VERU | 65 | Veru Set To Surge On Potential FDA Approval Of Unovoxarm (sp) | 6.07 | 25.00 | 312% | 2025-09-25 | 2025-10-10 | 15 | 96 |
| 111 | 2025-07-07 | VIVS | 65 | VivoSim Labs Set To Transform Drug Testing With Cutting Edge NAMkind™ Technology | 1.57 | 3.50 | 123% | 2025-08-01 | 2025-12-31 | 152 | 4 |
| 110 | 2025-07-07 | IMDX | 65 | Insight Molecular Diagnostics Nears Breakout On FDA Catalyst | 2.85 | 5.00 | 75% | 2025-07-29 | 2025-08-29 | 31 | 86 |
| 109 | 2025-07-07 | TRAW | 65 | Traws Pharma Nears Key Clinical Catalysts; Set For Growth | 1.45 | 3.50 | 141% | 2025-09-25 | 2025-10-10 | 15 | 8 |
| 108 | 2025-07-07 | CELU | 65 | Celularity Set To Surge On Imminent FDA Approvals And Global Expansion | 1.98 | 5.50 | 178% | 2025-09-25 | 2025-10-10 | 15 | 47 |
| 107 | 2025-07-07 | DTIL | 70 | Promising FDA Designation Poised To Propel Precision BioSciences | 4.34 | 12.00 | 176% | 2025-12-28 | 2026-01-31 | 34 | 47 |
| 106 | 2025-07-07 | ATRA | 65 | Atara Biotherapeutics Poised For Breakthrough With ATA3219 | 8.47 | 14.00 | 65% | 2025-08-20 | 2025-09-30 | 41 | 48 |
| 105 | 2025-07-07 | VRCA | 65 | Verrica Poised For Breakout With Pivotal Clinical Trials | 0.7067 | 4.00 | 466% | 2025-10-01 | 2025-12-31 | 91 | 49 |
| 104 | 2025-07-07 | MRKR | 65 | Marker Therapeutics Poised For Breakout With Key Clinical Results Imminent | 1.60 | 2.80 | 75% | 2025-07-12 | 2025-08-05 | 24 | 17 |
| 103 | 2025-07-07 | SNES | 65 | SenesTech Set For Growth With Global Expansion And Innovative Products | 5.14 | 10.00 | 95% | 2025-10-01 | 2026-01-31 | 122 | 10 |
| 102 | 2025-07-07 | HYPD | 65 | Hyperion DeFi Aims For Breakthrough In Blockchain And Pharma Integration | 14.36 | 22.50 | 57% | 2025-09-20 | 2025-10-25 | 35 | 73 |
| 101 | 2025-07-07 | RPTX | 65 | Repare Therapeutics Poised For Breakout With Promising Trial Outcomes | 1.44 | 2.80 | 94% | 2025-09-25 | 2025-11-30 | 66 | 60 |
| 100 | 2025-07-07 | SNGX | 65 | Soligenix Set For Breakthrough With HyBryte™ Phase 3 Trial | 1.20 | 4.50 | 275% | 2025-10-01 | 2026-03-31 | 181 | 4 |
| 99 | 2025-07-07 | MTNB | 65 | Matinas BioPharma Set To Surge On Pivotal Phase 3 Results | 0.9172 | 1.45 | 58% | 2025-09-25 | 2025-10-10 | 15 | 5 |
| 98 | 2025-07-07 | STEM | 65 | Stem Inc: Poised For Breakout With Strategic Shift And Clean Energy Demand | 8.61 | 12.00 | 39% | 2025-07-15 | 2025-08-15 | 31 | 56 |
| 97 | 2025-07-07 | INM | 65 | InMed Set For Breakout Amid Promising Alzheimer's Trial | 2.91 | 5.50 | 89% | 2025-08-01 | 2025-09-30 | 60 | 10 |
| 96 | 2025-07-07 | RKDA | 65 | Arkadia Biosciences Set For Growth Post Roosevelt Merger | 4.65 | 6.50 | 40% | 2025-08-25 | 2025-09-10 | 16 | 6 |
| 95 | 2025-07-07 | CYCN | 65 | Cyclerion Set For Breakout With Key Clinical Readouts | 3.36 | 7.50 | 123% | 2025-11-01 | 2026-03-01 | 120 | 9 |
| 94 | 2025-07-07 | STRO | 65 | Sutro Biopharma Set For Breakthrough With Pivotal Trial Results | 0.7632 | 2.20 | 188% | 2025-12-20 | 2026-01-15 | 26 | 60 |
| 93 | 2025-07-07 | HOOK | 65 | HOOKIPA Set For Breakout On Strong Clinical Progress And Strategic Alliances | 1.23 | 2.75 | 124% | 2025-12-01 | 2026-02-28 | 89 | 15 |
| 92 | 2025-07-07 | CLRB | 65 | Promising Outlook For Cellectar Amid Clinical Advances | 4.80 | 12.00 | 150% | 2025-07-25 | 2025-08-15 | 21 | 14 |
| 91 | 2025-07-07 | STTK | 65 | Shattuck Labs Poised For Breakout With Upcoming IND Filing | 0.8334 | 1.50 | 80% | 2025-08-01 | 2025-09-30 | 60 | 38 |
| 90 | 2025-07-07 | CRIS | 65 | Curis Poised For Breakout With Promising Trial Outcomes | 1.81 | 2.90 | 60% | 2025-09-25 | 2025-10-10 | 15 | 23 |
| 89 | 2025-07-07 | YMAB | 65 | Y MAbs Poised For Breakout With Upcoming Clinical Trial Results | 4.30 | 14.58 | 239% | 2025-09-20 | 2025-10-20 | 30 | 204 |
| 88 | 2025-07-07 | XBIO | 65 | Xenetic Poised For Breakout With Upcoming DNase IND Filing | 3.70 | 5.50 | 49% | 2025-11-01 | 2025-12-31 | 60 | 6 |
| 87 | 2025-07-07 | DARE | 65 | Dare Bioscience Nears Potential FDA Approvals, Promising Upside | 2.40 | 6.50 | 171% | 2025-10-01 | 2025-12-31 | 91 | 24 |
| 86 | 2025-07-07 | GEVO | 65 | Gevo Set For Breakout As Green Fuel Innovations Gain Traction | 1.50 | 2.80 | 87% | 2025-07-20 | 2025-08-10 | 21 | 316 |
| 85 | 2025-07-07 | AMS | 65 | American Shared Set To Surge On New Medical Technology Approvals | 2.49 | 3.50 | 41% | 2025-08-01 | 2025-12-31 | 152 | 16 |
| 84 | 2025-07-07 | SYBX | 65 | Synlogic Set For Breakthrough With Upcoming PKU Trial | 1.18 | 2.50 | 112% | 2025-08-01 | 2025-10-15 | 75 | 14 |
| 83 | 2025-07-07 | FBIO | 65 | Fortress Biotech Set For Breakthrough With Cosibelimab FDA Decision | 1.88 | 3.50 | 86% | 2025-09-20 | 2025-12-31 | 102 | 55 |
| 82 | 2025-07-07 | CUE | 65 | "Cue Biopharma Set For Breakthrough With Promising Phase 1 Results" | 0.6952 | 2.50 | 260% | 2025-11-01 | 2026-01-31 | 91 | 59 |
| 81 | 2025-07-07 | ORGO | 65 | Organogenesis Set For Growth With Upcoming Earnings And Approvals | 4.25 | 6.50 | 53% | 2025-08-01 | 2025-08-31 | 30 | 464 |
| 80 | 2025-07-07 | CHRS | 65 | Coherus Oncology: Poised For Breakthrough With Robust Oncology Pipeline | 0.8100 | 2.50 | 209% | 2025-08-01 | 2025-11-30 | 121 | 85 |
| 79 | 2025-07-07 | MRSN | 65 | Mersana Poised For Breakout With Promising Clinical Trials | 0.2895 | 1.50 | 418% | 2025-10-01 | 2025-12-31 | 91 | 37 |
| 78 | 2025-07-07 | NERV | 65 | Minerva Set For Breakout With Upcoming FDA Decision On Roluperidone | 1.65 | 3.50 | 112% | 2025-08-01 | 2025-09-30 | 60 | 13 |
| 77 | 2025-07-07 | RGNX | 65 | REGENXBIO Set For Breakthrough With Impending FDA Approval | 8.74 | 35.00 | 300% | 2025-10-01 | 2026-01-31 | 122 | 414 |
| 76 | 2025-07-07 | ARCT | 65 | Arcturus Therapeutics: Poised For Breakout With RNA Innovations | 13.78 | 28.00 | 103% | 2025-08-01 | 2025-11-30 | 121 | 353 |
| 75 | 2025-07-07 | NATR | 65 | Nature's Sunshine Set For Growth Surge Post Q2 Earnings | 15.59 | 18.50 | 19% | 2025-07-15 | 2025-09-30 | 77 | 273 |
| 74 | 2025-07-07 | ALEC | 65 | Alector Eyes Breakthrough With Pivotal Latozinemab Trial Results | 1.51 | 3.50 | 132% | 2025-10-20 | 2025-12-31 | 72 | 140 |
| 73 | 2025-07-07 | EDIT | 65 | Editas Medicine Set For Breakout On Upcoming Clinical Results | 2.57 | 4.20 | 63% | 2025-11-28 | 2025-12-15 | 17 | 184 |
| 72 | 2025-07-07 | ASRT | 35 | Assertio Faces Turnaround Challenges Amid Legal Headwinds | 0.6530 | 1.00 | 53% | 2025-08-01 | 2025-08-31 | 30 | 61 |
| 71 | 2025-07-07 | VYGR | 65 | Voyager Poised For Breakthrough With Novel Gene Therapies | 3.20 | 8.50 | 166% | 2025-10-01 | 2026-04-30 | 211 | 172 |
| 70 | 2025-07-06 | DERM | 65 | Journey Medical Set For Surge With Emrosi™ Launch | 7.10 | 9.75 | 37% | 2025-07-10 | 2025-09-30 | 82 | 162 |
| 69 | 2025-07-06 | JAGX | 65 | Jaguar Health Poised For Breakthrough With Crofelemer Trials | 2.58 | 5.75 | 123% | 2025-11-01 | 2026-05-31 | 211 | 4 |
| 68 | 2025-07-06 | NBY | 60 | Investor Alert: NovaBay's Pivotal Decision Point Imminent | 0.6290 | 1.25 | 99% | 2025-08-01 | 2025-08-31 | 30 | 3 |
| 67 | 2025-07-06 | CPHI | 55 | China Pharma Poised For Growth With New Therapeutic Device Launch | 1.84 | 2.50 | 36% | 2025-08-01 | 2025-09-30 | 60 | 6 |
| 66 | 2025-07-06 | ORMP | 65 | Oramed Set To Transform Diabetes Treatment With Oral Insulin Breakthrough | 2.18 | 3.50 | 61% | 2025-11-20 | 2025-12-15 | 25 | 92 |
| 65 | 2025-07-06 | SPRO | 65 | Spero Therapeutics Nears Potential FDA Approval, Stock Poised To Surge | 2.91 | 5.50 | 89% | 2025-08-25 | 2025-09-10 | 16 | 162 |
| 64 | 2025-07-06 | CTMX | 65 | CytomX Set To Surge On Promising Cancer Trial Results | 2.50 | 5.50 | 120% | 2025-07-15 | 2025-08-15 | 31 | 358 |
| 63 | 2025-07-06 | ETON | 65 | Eton Pharmaceuticals Set For Breakout Amidst Key FDA Approvals | 14.45 | 29.67 | 105% | 2025-07-12 | 2025-08-25 | 44 | 382 |
| 62 | 2025-07-06 | FF | 65 | FutureFuel: Strategic Shifts Poised For Q2 Catalyst Impact | 4.17 | 5.50 | 32% | 2025-08-07 | 2025-08-15 | 8 | 170 |
| 61 | 2025-07-06 | AGEN | 65 | Agenus Set For Breakout On Promising Phase 2 Cancer Trial Results | 6.07 | 9.50 | 57% | 2025-11-25 | 2025-12-10 | 15 | 135 |
| 60 | 2025-07-06 | ICCC | 65 | ImmuCell Poised For Growth With Pending FDA Approval Of Re Tain | 6.40 | 8.50 | 33% | 2025-10-01 | 2025-12-31 | 91 | 63 |
| 59 | 2025-07-06 | APVO | 65 | Aptevo Set To Transform With Upcoming AML Trial Results | 3.04 | 6.50 | 114% | 2025-11-01 | 2025-12-15 | 44 | 9 |
| 58 | 2025-07-06 | TXMD | 65 | TherapeuticsMD: Royalty Strategy Set To Catalyze Growth | 1.18 | 1.75 | 48% | 2025-10-27 | 2025-11-10 | 14 | 14 |
| 57 | 2025-07-06 | MTEX | 65 | Mannatech Gears Up For Strategic Growth And Market Expansion | 9.20 | 15.00 | 63% | 2025-08-01 | 2025-09-30 | 60 | 18 |
| 56 | 2025-07-06 | FTK | 75 | Flotek Poised For Breakout On Earnings Momentum | 14.84 | 18.00 | 21% | 2025-07-10 | 2025-08-07 | 28 | 441 |
| 55 | 2025-07-06 | ADAP | 70 | Adaptimmune Set For Breakout With Pending FDA Approval | 0.2500 | 1.50 | 500% | 2025-07-30 | 2025-08-20 | 21 | 64 |
| 54 | 2025-07-06 | GPRE | 65 | Green Plains Poised For Growth With Sustainable Innovations | 6.98 | 9.50 | 36% | 2025-07-20 | 2025-08-20 | 31 | 394 |
| 53 | 2025-07-06 | CPIX | 65 | Promising Clinical Developments Propel Cumberland's Market Prospects | 3.15 | 5.25 | 67% | 2025-09-25 | 2025-12-15 | 81 | 50 |
| 52 | 2025-07-06 | PBYI | 65 | Puma Biotech Set For Gain Amid Promising Trial Results | 3.58 | 4.50 | 26% | 2025-09-25 | 2025-10-10 | 15 | 170 |
| 51 | 2025-07-06 | TENX | 60 | Tenax Poised For Breakout With Pivotal Phase 3 Data | 5.81 | 12.00 | 107% | 2025-12-01 | 2026-06-30 | 211 | 24 |
| 50 | 2025-07-06 | RIGL | 75 | Rigel Poised For Breakout With Impending Clinical Results | 18.93 | 25.50 | 35% | 2025-07-10 | 2025-08-15 | 36 | 335 |
| 49 | 2025-07-06 | IRWD | 65 | Ironwood Gears Up For Apraglutide NDA, Potential Market Stir | 0.7660 | 1.20 | 57% | 2025-07-20 | 2025-10-31 | 103 | 126 |
| 48 | 2025-07-06 | XOMA | 65 | XOMA Set For Growth With Strategic Turnstone Acquisition | 26.96 | 35.00 | 30% | 2025-08-01 | 2025-09-30 | 60 | 330 |
| 47 | 2025-07-06 | PRPH | 60 | ProPhase Labs Poised For Breakout With BE Smart Launch | 0.4185 | 1.00 | 139% | 2025-12-18 | 2026-01-15 | 28 | 14 |
| 46 | 2025-07-06 | EBS | 65 | Emergent BioSolutions Set For Breakout On New Approvals And Contracts | 6.99 | 10.50 | 50% | 2025-11-01 | 2025-12-31 | 60 | 346 |
| 45 | 2025-07-04 | ATNM | 65 | Actinium Set For Breakout Amid Pivotal Trial Updates | 1.44 | 3.50 | 143% | 2025-07-20 | 2025-08-15 | 26 | 51 |
| 44 | 2025-07-04 | PLX | 65 | Protalix Poised For Breakout With Upcoming FDA Approvals | 1.54 | 2.50 | 62% | 2025-07-20 | 2025-08-10 | 21 | 123 |
| 43 | 2025-07-04 | CRBP | 65 | Corbus Pharmaceuticals: Poised For Breakthrough With CRB 913 | 7.71 | 15.00 | 95% | 2025-09-25 | 2026-03-30 | 186 | 91 |
| 42 | 2025-07-04 | CVM | 65 | Multikine Nears Approval, Cel Sci Poised For Breakout | 2.49 | 12.00 | 382% | 2025-10-01 | 2026-01-31 | 122 | 13 |
| 41 | 2025-07-04 | PULM | 65 | Strategic Merger And Clinical Advances Propel Pulmatrix | 6.53 | 8.50 | 30% | 2025-07-10 | 2025-08-15 | 36 | 26 |
| 40 | 2025-07-04 | OGEN | 65 | Oragenics Set For Breakout Amid Promising ONP 002 Phase 2 Trials | 1.53 | 4.50 | 194% | 2025-12-25 | 2026-04-01 | 97 | 3 |
| 39 | 2025-07-04 | SCYX | 65 | SCYNEXIS Set For Breakout Amid Promising Trial Outcomes | 0.7314 | 2.50 | 242% | 2025-11-01 | 2025-12-31 | 60 | 29 |
| 38 | 2025-07-04 | LPCN | 65 | Lipocine Eyes Breakthrough With Upcoming FDA Decision | 3.10 | 8.50 | 174% | 2025-10-01 | 2025-11-30 | 60 | 17 |
| 37 | 2025-07-04 | FGEN | 65 | FibroGen Poised For Recovery With Key Trial Updates | 5.61 | 9.00 | 60% | 2025-07-25 | 2025-08-05 | 11 | 21 |
| 36 | 2025-07-04 | MEIP | 65 | MEI Pharma Poised For Breakout With Upcoming Clinical Results | 2.68 | 5.50 | 105% | 2025-09-25 | 2025-10-30 | 35 | 15 |
| 35 | 2025-07-04 | XNCR | 65 | Xencor Poised For Breakout With Promising Clinical Trials | 8.42 | 15.00 | 78% | 2025-12-20 | 2026-01-10 | 21 | 598 |
| 34 | 2025-07-04 | KPTI | 65 | Karyopharm Set For Potential Breakout Amid Pivotal Trial Results | 4.39 | 8.50 | 94% | 2025-11-20 | 2025-12-15 | 25 | 39 |
| 33 | 2025-07-04 | PRTA | 65 | Prothena Set For Breakout With Upcoming Clinical Trial Results | 6.44 | 24.00 | 273% | 2025-07-20 | 2025-09-30 | 72 | 333 |
| 32 | 2025-07-04 | IBIO | 65 | AI Driven IBio Poised For Clinical Breakthroughs And Market Impact | 0.7410 | 1.50 | 102% | 2025-11-01 | 2026-05-01 | 181 | 12 |
| 31 | 2025-07-04 | DRRX | 65 | Durect Set To Transform Hepatitis Treatment Landscape | 0.6667 | 2.50 | 275% | 2025-09-01 | 2025-11-30 | 90 | 18 |
| 30 | 2025-07-03 | CYCC | 60 | Critical Clinical Trials Approach For Cyclacel Amid Financial Turmoil | 3.54 | 18.00 | 408% | 2025-10-25 | 2025-11-30 | 36 | 8 |
| 29 | 2025-07-03 | TBPH | 65 | Theravance Biopharma Poised For Growth With Key Clinical Trials | 11.15 | 15.50 | 39% | 2025-10-01 | 2026-01-31 | 122 | 529 |
| 28 | 2025-07-03 | CLSD | 65 | Clearside Biomedical Poised For Breakout With Pioneering Eye Treatment Trials | 12.18 | 45.00 | 269% | 2025-06-01 | 2025-09-30 | 121 | 63 |
| 27 | 2025-07-03 | TNXP | 65 | Tonix Pharmaceuticals Poised For Breakthrough With FDA Decision | 35.48 | 50.00 | 41% | 2025-08-10 | 2025-08-20 | 10 | 261 |
| 26 | 2025-07-03 | SIGA | 65 | SIGA Set For Surge As TPOXX Phase 3 Trials Conclude | 6.69 | 9.50 | 42% | 2025-09-25 | 2025-10-10 | 15 | 469 |
| 25 | 2025-07-03 | VTVT | 65 | VTv Therapeutics Poised For Breakthrough With Diabetes Drug | 15.07 | 28.00 | 86% | 2025-10-01 | 2026-01-10 | 101 | 41 |
| 24 | 2025-07-03 | AMRN | 65 | Amarin Poised For Breakout With Key Approvals And Global Expansion | 16.73 | 18.50 | 11% | 2025-07-10 | 2025-08-10 | 31 | 329 |
| 23 | 2025-07-03 | FATE | 65 | Fate Therapeutics Poised For Breakout On Clinical Catalysts | 1.12 | 5.50 | 391% | 2025-11-01 | 2025-12-31 | 60 | 128 |
| 22 | 2025-07-03 | ENTA | 65 | Enanta Set For Breakout On Clinical Trial Catalysts | 7.89 | 16.50 | 109% | 2025-09-25 | 2025-10-10 | 15 | 161 |
| 21 | 2025-07-03 | NKTR | 70 | Promising Phase 2b Trials Propel Nektar's Investment Potential | 24.76 | 35.00 | 41% | 2025-07-30 | 2025-08-30 | 31 | 368 |
| 20 | 2025-07-03 | QURE | 70 | UniQure Set For Breakout Amid Promising Gene Therapy Advances | 14.42 | 35.00 | 143% | 2025-07-10 | 2025-10-14 | 96 | 779 |
| 19 | 2025-07-03 | XBIT | 65 | XBiotech Poised For Breakout With Upcoming Phase II Trial Results | 3.18 | 6.50 | 104% | 2025-07-10 | 2026-03-20 | 253 | 87 |
| 18 | 2025-07-03 | MGNX | 60 | MacroGenics Poised For Breakthrough Amid Clinical Trials | 1.46 | 2.50 | 71% | 2025-09-25 | 2025-10-10 | 15 | 80 |
| 17 | 2025-07-02 | VTGN | 65 | Promising Outlook For Vistagen With Upcoming Phase III Results | 2.00 | 4.00 | 100% | 2025-10-01 | 2025-12-31 | 91 | 61 |
| 16 | 2025-07-02 | ABEO | 65 | Abeona Therapeutics Nears Transformative FDA Decision | 5.89 | 10.00 | 70% | 2025-07-10 | 2025-08-10 | 31 | 302 |
| 15 | 2025-07-02 | ASMB | 65 | Assembly Biosciences Near Breakout; Key Clinical Trials In Focus | 18.14 | 25.00 | 38% | 2025-09-25 | 2025-12-15 | 81 | 130 |
| 14 | 2025-07-02 | VSTM | 70 | Verastem Poised For Breakout With Imminent FDA Approval | 4.80 | 6.50 | 35% | 2025-07-20 | 2025-08-15 | 26 | 229 |
| 13 | 2025-07-02 | ACRS | 65 | Aclaris Eyes Breakout On Upcoming Clinical Results | 1.44 | 3.00 | 108% | 2025-11-28 | 2026-01-15 | 48 | 169 |
| 12 | 2025-07-02 | AKBA | 65 | Akebia Therapeutics Set For Breakout Amid Strong Clinical Outcomes | 3.62 | 6.50 | 80% | 2025-07-15 | 2025-08-15 | 31 | 982 |
| 11 | 2025-07-02 | HRTX | 65 | Anticipating Heron Therapeutics' Breakout On Phase 3 Results | 2.20 | 4.50 | 105% | 2025-11-20 | 2025-12-15 | 25 | 330 |
| 10 | 2025-07-02 | CDXS | 70 | Codexis Set To Surge On Breakthrough ECO Synthesis Platform | 2.77 | 7.50 | 171% | 2025-10-01 | 2025-10-31 | 30 | 209 |
| 9 | 2025-07-02 | MCRB | 65 | Seres Therapeutics Set For Breakout On Impending Clinical Results | 11.87 | 15.00 | 26% | 2025-09-25 | 2025-10-10 | 15 | 83 |
| 8 | 2025-07-02 | MNOV | 65 | MediciNova Set For Breakout With Key Clinical Trials Results | 1.25 | 5.00 | 300% | 2025-11-25 | 2026-01-10 | 46 | 67 |
| 7 | 2025-07-02 | CAPR | 70 | Capricor Poised For Breakout With Promising DMD Therapy Updates | 10.25 | 18.00 | 76% | 2025-08-01 | 2025-09-30 | 60 | 465 |
| 6 | 2025-07-02 | SAGE | 65 | Sage Therapeutics Set For Breakout On Upcoming Trial Results | 9.20 | 12.50 | 36% | 2025-07-15 | 2025-08-15 | 31 | 581 |
| 5 | 2025-07-02 | SGMO | 65 | Sangamo Poised For Breakout With Forthcoming BLA Submission | 0.5269 | 4.50 | 754% | 2025-12-01 | 2026-06-30 | 211 | 137 |
| 4 | 2025-07-02 | GALT | 65 | Promising Trial Results Could Propel Galectin Therapeutics | 2.18 | 6.00 | 175% | 2025-09-20 | 2025-10-20 | 30 | 149 |
| 3 | 2025-07-02 | OMER | 65 | Omeros Set For Potential Breakout Ahead Of FDA Decision | 3.20 | 8.00 | 150% | 2025-09-20 | 2025-10-05 | 15 | 195 |
| 2 | 2025-07-02 | CRMD | 65 | CorMedix Set For Breakout With DefenCath's Outpatient Launch | 11.62 | 18.00 | 55% | 2025-10-25 | 2026-01-25 | 92 | 1113 |
| 1 | 2025-07-02 | LXRX | 65 | Lexicon Pharmaceuticals Set For Breakout Amidst Clinical Advances | 0.9010 | 3.00 | 233% | 2025-09-20 | 2025-12-31 | 102 | 338 |
